Publication | Closed Access

14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

Second-line TreatmentOncologyGastrointestinal OncologyPathologyColorectal CancerMetastatic Colorectal CancerRandomized Phase 3Cancer TreatmentMedicineRadiation OncologyMolecular Oncology